Business Context and Reporting Period
This Form 8-K reports on the results of the 2026 Annual Meeting of Stockholders held by MacroGenics, Inc. on May 19, 2026. The filing details the voting outcomes for four proposals presented to shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting results.
Material Changes and Voting Results
A total of 36,744,013 shares were present or represented by proxy, representing approximately 58% of the 63,560,068 outstanding shares entitled to vote. All four proposals were approved:
- Proposal 1 (Director Election): All four Class I director nominees (Scott Koenig, Federica O'Brien, Eric Risser, and one unnamed nominee in the text structure) were elected. Broker non-votes totaled 9,397,708 shares.
- Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026. Votes For: 36,689,683; Against: 40,552.
- Proposal 3 (Executive Compensation): Stockholders approved the advisory vote on named executive officer compensation. Votes For: 26,624,952; Against: 526,125.
- Proposal 4 (Equity Plan Amendment): Stockholders approved an amendment to the 2023 Equity Incentive Plan to increase the number of shares available for issuance by 1,250,000 shares. Votes For: 25,600,112; Against: 1,671,102.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, or contingencies beyond the standard disclosure of voting results.
Investor Verification Checklist
- Verify the impact of the 1,250,000 share increase in the 2023 Equity Incentive Plan on potential future dilution.
- Review the definitive proxy statement filed on April 8, 2026, for detailed biographies of the newly elected directors and executive compensation specifics.
- Confirm the total number of outstanding shares (63,560,068) against subsequent filings to monitor any changes in capital structure.